Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Nurexone Biologic: Jetzt diese wirklich einzigartige Chance ergreifen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 870513 | ISIN: US7493604000 | Ticker-Symbol: RC2
Berlin
26.04.24
08:08 Uhr
17,200 Euro
-0,100
-0,58 %
1-Jahres-Chart
RCM TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
RCM TECHNOLOGIES INC 5-Tage-Chart
GlobeNewswire (Europe)
247 Leser
Artikel bewerten:
(1)

RCM Technologies, Inc. Announces Third Quarter Results

PENNSAUKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the adaptation and deployment of advanced engineering, specialty health care, and information technology services, today announced financial results for the thirteen and thirty-nine weeks ended September 30, 2023.

RCM Technologies reported revenue of $58.0 million for the thirteen weeks ended September 30, 2023 (the current period), a decrease of 0.2% compared to $58.2 million for the thirteen weeks ended October 1, 2022 (the comparable prior-year period). Gross profit was $17.3 million for the current period, a 0.4% decrease compared to $17.4 million for the comparable prior-year period. The Company experienced GAAP operating income of $4.3 million for the current period compared to $4.8 million for the comparable prior-year period. The Company experienced GAAP net income of $3.8 million, or $0.46 per diluted share, for the current period compared to $3.5 million, or $0.33 per diluted share, for the comparable prior-year period. The Company experienced adjusted EBITDA (non-GAAP) of $4.6 million for the current period compared to $4.8 million for the comparable prior-year period.

RCM Technologies reported revenue of $192.2 million for the thirty-nine weeks ended September 30, 2023 (the current period), a decrease of 10.4% compared to $214.5 million for the thirty-nine weeks ended October 1, 2022 (the comparable prior-year period). Gross profit was $55.1 million for the current period, a 11.8% decrease compared to $62.5 million for the comparable prior-year period. The Company experienced GAAP operating income of $15.8 million for the current period compared to $22.0 million for the comparable prior-year period. The Company experienced GAAP net income of $11.6 million, or $1.33 per diluted share, for the current period compared to $16.1 million, or $1.52 per diluted share, for the comparable prior-year period. The Company experienced adjusted EBITDA (non-GAAP) of $16.3 million for the current period compared to $22.5 million for the comparable prior-year period.

Bradley Vizi, Executive Chairman of RCM Technologies, commented, "The cadence of our business continues to accelerate as we move through the year. As such, we expect the fourth quarter to be our strongest, and continue to be confident that the long-term outlook for RCM is bright."

Kevin Miller, Chief Financial Officer of RCM Technologies, commented, "With our continued focus on return on equity, the productivity of our revenue improved in the third quarter of 2023, resulting in 180 basis points of gross margin improvement over the second quarter of 2023."

Conference Call
On Thursday, November 9, 2023, RCM Technologies will host a conference call to discuss these results. The call will begin at 11:00 a.m. Eastern Time. The dial-in number is (800) 285-6670.

About RCM
RCM Technologies, Inc. is a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the adaptation and deployment of advanced information technology and engineering services. RCM is an innovative leader in delivering these solutions to commercial and government sectors. RCM is also a provider of specialty healthcare services to major health care institutions and educational facilities. RCM's offices are located in major metropolitan centers throughout North America and Serbia. Additional information can be found at www.rcmt.com.

The statements contained in this release that are not purely historical are forward-looking statements within the Private Securities Litigation Reform Act of 1995. They are subject to various risks, uncertainties, and other factors that could cause the Company's actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should," "are confident" or similar expressions. In addition, statements that are not historical should also be considered forward-looking statements. These statements are based on assumptions that we have made in light of our experience in the industry, and our perceptions of historical trends, current conditions, expected future developments, and other factors we believe are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to demand for the Company's services, expectations regarding our future revenues and other financial results, our pipeline, and potential project wins, and our expectations for investment and growth in our business. Such statements are based on current expectations that involve several known and unknown risks, uncertainties, and other factors, which may cause actual events to be materially different from those expressed or implied by such forward-looking statements. Risk, uncertainties, and other factors may emerge from time to time that could cause the Company's actual results to differ from those indicated by the forward-looking statements. Investors are directed to consider such risks, uncertainties, and other factors described in documents filed by the Company with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company assumes no obligation (and expressly disclaims any such obligation) to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.

Tables to Follow

RCM Technologies, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In Thousands, Except Per Share Amounts)

Thirteen Weeks Ended
September 30,
2023
October 1,
2022
Revenue$58,049 $58,152
Cost of services 40,768 40,794
Gross profit 17,281 17,358
Selling, general and administrative 12,662 12,551
Depreciation and amortization of property and equipment 243 266
Amortization of acquired intangible assets 45 -
Gain on sale of assets - (219)
Operating income 4,331 4,760
Other expense (income), net 141 (55)
Income before income taxes 4,190 4,815
Income tax expense 434 1,297
Net income$3,756 $3,518
Diluted net earnings per share data$0.46 $0.33
Diluted weighted average shares outstanding 8,196,330 10,522,158
Thirty-Nine Weeks Ended
September 30,
2023
October 1,
2022
Revenue$192,209 $214,459
Cost of services 137,144 151,998
Gross profit 55,065 62,461
Selling, general and administrative 38,782 39,962
Depreciation and amortization of property and equipment 756 729
Amortization of acquired intangible assets 136 -
Gain on sale of assets (395) (219)
Operating income 15,786 21,989
Other expense (income), net 965 (31)
Income before income taxes 14,821 22,020
Income tax expense 3,245 5,968
Net income$11,576 $16,052
Diluted net earnings per share data$1.33 $1.52
Diluted weighted average shares outstanding 8,730,998 10,566,816



RCM Technologies, Inc.
Supplemental Operating Results on a Non-GAAP Basis
(Unaudited)
(In Thousands)

The following non-GAAP measures, which adjust for the categories of expenses described below, are non-GAAP financial measures. Our management believes that these non-GAAP financial measures ("Adjusted operating income," "EBITDA" and "Adjusted EBITDA") are useful information for investors, shareholders, and other stakeholders of our Company in gauging our results of operations on an ongoing basis and to enhance investors' overall understanding of our current financial performance and period-to-period comparisons. Adjusted operating income, EBITDA and Adjusted EBITDA should not be considered alternatives to net income as an indicator of performance. In addition, Adjusted operating income, EBITDA and Adjusted EBITDA do not take into account changes in certain assets and liabilities and interest and income taxes that can affect cash flows. We do not intend the presentation of these non-GAAP measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP. These non-GAAP measures should be read-only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

The following unaudited table presents the Company's GAAP net income and the corresponding adjustments used to calculate Adjusted operating income, EBITDA and Adjusted EBITDA for the thirteen and thirty-nine weeks ended September 30, 2023 and October 1, 2022.

Thirteen Weeks Ended Thirty-Nine Weeks Ended
September 30,
2023
October 1,
2022
September 30,
2023
October 1,
2022
GAAP net income$3,756 $3,518 $11,576 $16,052
Income tax expense 434 1,297 3,245 5,968
Interest expense, net 185 35 970 201
Depreciation of property and equipment 243 266 756 729
Amortization of acquired intangible assets 45 - 136 -
EBITDA (non-GAAP)$4,663 $5,116 $16,683 $22,950
Adjustments
Gain on sale of assets - (219) (395) (219)
Gain on foreign currency transactions (44) (90) (5) (232)
Adjusted EBITDA (non-GAAP)$4,619 $4,807 $16,283 $22,499



RCM Technologies, Inc.
Summary of Selected Income Statement Data
(Unaudited)
(In Thousands)

Thirteen Weeks Ended September 30, 2023
Specialty
Health Care
Engineering Life Sciences
and IT


Consolidated
Revenue$24,895 $22,452 $10,702 $58,049
Cost of services 17,438 16,846 6,484 40,768
Gross profit$7,457 $5,606 $4,218 $17,281
Gross profit margin 30.0% 25.0% 39.4% 29.8%
Thirteen Weeks Ended October 1, 2022
Specialty
Health Care
Engineering Life Sciences
and IT


Consolidated
Revenue$27,997 $20,922 $9,233 $58,152
Cost of services 19,014 15,594 6,186 40,794
Gross profit$8,983 $5,328 $3,047 $17,358
Gross profit margin 32.1% 25.5% 33.0% 29.8%
Thirty-Nine Weeks Ended September 30, 2023
Specialty
Health Care
Engineering Life Sciences
and IT


Consolidated
Revenue$99,553 $61,956 $30,700 $192,209
Cost of services 70,623 47,482 19,039 137,144
Gross profit$28,930 $14,474 $11,661 $55,065
Gross profit margin 29.1% 23.4% 38.0% 28.6%
Thirty-Nine Weeks Ended October 1, 2022
Specialty
Health Care
Engineering Life Sciences
and IT


Consolidated
Revenue$123,638 $61,726 $29,095 $214,459
Cost of services 86,772 45,653 19,573 151,998
Gross profit$36,866 $16,073 $9,522 $62,461
Gross profit margin 29.8% 26.0% 32.7% 29.1%



RCM Technologies, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In Thousands, Except Share Amounts)

September 30, December 31,
2023 2022
(Unaudited)
Current assets:
Cash and cash equivalents$654 $339
Accounts receivable, net 57,459 50,762
Transit accounts receivable 9,550 3,280
Prepaid expenses and other current assets 5,311 4,636
Total current assets 72,974 59,017
Property and equipment, net 2,221 2,098
Other assets:
Deposits 168 173
Goodwill 22,147 22,147
Operating right of use asset 2,976 3,665
Intangible assets, net 728 864
Total other assets 26,019 26,849
Total assets$101,214 $87,964
Current liabilities:
Accounts payable and accrued expenses$12,153 $14,147
Transit accounts payable 38,421 9,767
Accrued payroll and related costs 14,619 13,023
Finance lease payable 348 462
Income taxes payable 247 85
Operating right of use liability 884 1,349
Contingent consideration from acquisitions 300 472
Deferred revenue 335 1,119
Total current liabilities 67,307 40,424
Deferred income taxes, net, foreign 166 166
Deferred income taxes, net, domestic 1,652 1,495
Finance lease payable - 232
Contingent consideration from acquisitions, net of current position 1,671 1,970
Operating right of use liability, net of current position 2,382 2,932
Borrowings under line of credit 6,657 8,783
Total liabilities 79,835 56,002
Contingencies (note 15) - -
Stockholders' equity:
Preferred stock, $1.00 par value; 5,000,000 shares authorized;
no shares issued or outstanding - -
Common stock, $0.05 par value; 40,000,000 shares authorized;
17,660,999 shares issued and 7,900,190 shares outstanding at September 30, 2023 and 17,287,967 shares issued and 9,285,318 shares outstanding at December 31, 2022 880 863
Additional paid-in capital 116,146 113,878
Accumulated other comprehensive loss (2,858) (2,863)
Accumulated deficit (24,520) (36,096)
Treasury stock, 9,760,809 shares at September 30, 2023 and
8,002,649 shares at December 31, 2022, at cost (68,269) (43,820)
Total stockholders' equity 21,379 31,962
Total liabilities and stockholders' equity$101,214 $87,964



RCM Technologies, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In Thousands)

Thirteen Weeks Ended
September 30,
2023
October 1,
2022
Net income$3,756 $3,518
Adjustments to reconcile net income to cash used in operating activities 1,049 364
Changes in operating assets and liabilities:
Accounts receivable 4,143 (5,155)
Prepaid expenses and other current assets (987) 169
Net of transit accounts receivable and payable 1,556 (788)
Accounts payable and accrued expenses (785) 2,064
Accrued payroll and related costs 2,790 1,187
Right of use liabilities (333) (366)
Income taxes payable 15 (336)
Deferred revenue (169) (621)
Deposits 2 (11)
Total adjustments 7,281 (3,488)
Net cash provided by operating activities$11,037 $30
Net cash used in investing activities (315) (44)
Net cash used in financing activities (11,343) (2,293)
Effect of exchange rate changes on cash and cash equivalents 2 (44)
Increase in cash and cash equivalents($619)($2,351)
Common stock repurchase($3,389)($3,613)
Thirty-Nine Weeks Ended
September 30,
2023
October 1,
2022
Net income$11,576 $16,052
Adjustments to reconcile net income to cash used in operating activities 2,795 1,550
Changes in operating assets and liabilities:
Accounts receivable (6,696) (1,590)
Prepaid expenses and other current assets (675) 603
Net of transit accounts receivable and payable 22,384 (998)
Accounts payable and accrued expenses (1,798) 1,479
Accrued payroll and related costs 1,596 4,235
Right of use liabilities (1,016) (1,306)
Income taxes payable 162 2,574
Deferred revenue (784) (1,858)
Deposits 4 -
Total adjustments 15,972 4,689
Net cash provided by operating activities 27,548 $20,741
Net cash used in investing activities (480) (453)
Net cash used in financing activities (26,558) (19,468)
Effect of exchange rate changes on cash and cash equivalents (195) (294)
Increase in cash and cash equivalents$315 $526
Common stock repurchase($24,449)($6,394)
RCM Technologies, Inc.Tel: 856.356.4500Corporate Contacts:
2500 McClellan AvenueFax: 856.356.4600Bradley S. Vizi
Pennsauken, NJ 08109info@rcmt.comExecutive Chairman
www.rcmt.comKevin D. Miller
Chief Financial Officer

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2023 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.